These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 25154045)

  • 1. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
    Barker AF; O'Donnell AE; Flume P; Thompson PJ; Ruzi JD; de Gracia J; Boersma WG; De Soyza A; Shao L; Zhang J; Haas L; Lewis SA; Leitzinger S; Montgomery AB; McKevitt MT; Gossage D; Quittner AL; O'Riordan TG
    Lancet Respir Med; 2014 Sep; 2(9):738-49. PubMed ID: 25154045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of Life Questionnaire-Bronchiectasis: final psychometric analyses and determination of minimal important difference scores.
    Quittner AL; O'Donnell AE; Salathe MA; Lewis SA; Li X; Montgomery AB; O'Riordan TG; Barker AF
    Thorax; 2015 Jan; 70(1):12-20. PubMed ID: 25323621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
    McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
    Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
    Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
    Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials.
    Haworth CS; Bilton D; Chalmers JD; Davis AM; Froehlich J; Gonda I; Thompson B; Wanner A; O'Donnell AE
    Lancet Respir Med; 2019 Mar; 7(3):213-226. PubMed ID: 30658914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aztreonam lysine for inhalation solution: in cystic fibrosis.
    Plosker GL
    Drugs; 2010 Oct; 70(14):1843-55. PubMed ID: 20836577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Retsch-Bogart GZ; Burns JL; Otto KL; Liou TG; McCoy K; Oermann C; Gibson RL;
    Pediatr Pulmonol; 2008 Jan; 43(1):47-58. PubMed ID: 18041081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
    Oermann CM; Retsch-Bogart GZ; Quittner AL; Gibson RL; McCoy KS; Montgomery AB; Cooper PJ
    Pediatr Pulmonol; 2010 Nov; 45(11):1121-34. PubMed ID: 20672296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
    Wainwright CE; Quittner AL; Geller DE; Nakamura C; Wooldridge JL; Gibson RL; Lewis S; Montgomery AB
    J Cyst Fibros; 2011 Jul; 10(4):234-42. PubMed ID: 21441078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhaled aztreonam for chronic Burkholderia infection in cystic fibrosis: a placebo-controlled trial.
    Tullis DE; Burns JL; Retsch-Bogart GZ; Bresnik M; Henig NR; Lewis SA; Lipuma JJ
    J Cyst Fibros; 2014 May; 13(3):296-305. PubMed ID: 24176390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial.
    Rogers GB; Bruce KD; Martin ML; Burr LD; Serisier DJ
    Lancet Respir Med; 2014 Dec; 2(12):988-96. PubMed ID: 25458200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.
    Gilchrist FJ; Bui S; Gartner S; McColley SA; Tiddens H; Ruiz G; Stehling F; Alani M; Gurtovaya O; Bresnik M; Watkins TR; Frankovic B; Skov M;
    J Cyst Fibros; 2024 Jan; 23(1):80-86. PubMed ID: 37455237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial.
    Valery PC; Morris PS; Byrnes CA; Grimwood K; Torzillo PJ; Bauert PA; Masters IB; Diaz A; McCallum GB; Mobberley C; Tjhung I; Hare KM; Ware RS; Chang AB
    Lancet Respir Med; 2013 Oct; 1(8):610-620. PubMed ID: 24461664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
    Assael BM; Pressler T; Bilton D; Fayon M; Fischer R; Chiron R; LaRosa M; Knoop C; McElvaney N; Lewis SA; Bresnik M; Montgomery AB; Oermann CM;
    J Cyst Fibros; 2013 Mar; 12(2):130-40. PubMed ID: 22985692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.
    Elborn JS; Henig NR
    Expert Opin Pharmacother; 2010 Jun; 11(8):1373-85. PubMed ID: 20426707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
    Pesaturo KA; Horton ER; Belliveau P
    Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The RESPIRE trials: Two phase III, randomized, multicentre, placebo-controlled trials of Ciprofloxacin Dry Powder for Inhalation (Ciprofloxacin DPI) in non-cystic fibrosis bronchiectasis.
    Aksamit T; Bandel TJ; Criollo M; De Soyza A; Elborn JS; Operschall E; Polverino E; Roth K; Winthrop KL; Wilson R
    Contemp Clin Trials; 2017 Jul; 58():78-85. PubMed ID: 28495619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing effects of inhaled antibiotics in adults with non-cystic fibrosis bronchiectasis--experiences from recent clinical trials.
    Paredes Aller S; Quittner AL; Salathe MA; Schmid A
    Expert Rev Respir Med; 2018 Sep; 12(9):769-782. PubMed ID: 30025482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhaled aztreonam improves symptoms of cough and sputum production in patients with bronchiectasis: a
    Crichton ML; Lonergan M; Barker AF; Sibila O; Goeminne P; Shoemark A; Chalmers JD
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32265309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy and safety of inhaled antibiotics for the treatment of bronchiectasis in adults: a systematic review and meta-analysis.
    Laska IF; Crichton ML; Shoemark A; Chalmers JD
    Lancet Respir Med; 2019 Oct; 7(10):855-869. PubMed ID: 31405826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.